Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.

Trial Details

NCT ID
NCT05830500
Phase
PHASE4
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
RECRUITING
Cancer Type
Thyroid Cancer
Interventions
  • Anlotinib Hydrochloride Capsule
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Lanzhou, Gansu, China|36.05701,103.83987
  • Nanning, Guangxi, China|22.81667,108.31667
  • Shijiazhuang, Hebei, China|38.04139,114.47861

Key Eligibility Criteria

  • Patients voluntarily joined the study, signed the informed consent, and had good compliance;
  • Patients ≥18 years of age (at the time of signing the informed consent); Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score: 0-2…
  • Patients were pathologically confirmed as inoperable locally advanced or metastatic medullary thyroid carcinoma (MTC), possessing imaging or clinic…
  • Having at least one measurable lesion (assessed by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Thyroid Cancer Trials on Trialify →